Category: Top Story
-
Amphenol Shares Surge After Record Quarter and Dividend Hike on AI-Driven Demand
Amphenol Corp (NYSE:APH) saw its stock jump more than 8% in pre-market trading on Wednesday after reporting record third-quarter results and announcing a sharp increase to its dividend, fueled by strong demand from AI and data center infrastructure. The Connecticut-based connector manufacturer posted adjusted earnings of $0.93 per share, an 86% surge from a year…
-
Applied DNA Stock Surges on $27 Million PIPE Financing Deal
Applied DNA Sciences Inc. (NASDAQ:BNBX) saw its shares soar 50% in pre-market trading on Wednesday after the biotech firm announced it had successfully closed a private investment in public equity (PIPE) financing, raising roughly $27 million in gross proceeds. The financing round, led by a mix of institutional DeFi and TradFi investors, consisted of $15.3…
-
PROG Holdings Shares Climb After Beating Q3 Earnings Expectations
PROG Holdings, Inc. (NYSE:PRG) saw its stock rise more than 2% in pre-market trading on Wednesday after posting third-quarter earnings that surpassed Wall Street forecasts, despite ongoing pressure on consumer spending. The lease-to-own fintech company reported adjusted earnings of $0.90 per share, topping the analyst estimate of $0.74. Revenue reached $595.1 million, ahead of the…
-
Dow Jones, S&P, Nasdaq, Futures, Wall Street Set for Uneven Open as Trade Tensions and Earnings Shape Sentiment
U.S. stock futures were little changed early Wednesday, signaling a cautious open as investors weighed geopolitical uncertainty against a busy slate of corporate earnings. Renewed doubts over U.S.–China trade relations added a layer of tension to the market tone following fresh remarks from President Donald Trump. During a lunch with Republican lawmakers in the White…
-
Winnebago shares surge 11% as Q4 earnings and revenue surpass forecasts
Winnebago Industries (NYSE:WGO) delivered fourth-quarter fiscal 2025 results that came in well ahead of expectations on Wednesday, fueled by favorable product mix and strategic pricing actions. The strong results sent the company’s shares soaring 11.45% in premarket trading. Adjusted earnings per share reached $0.71, topping the $0.51 analyst consensus by nearly 40%. Quarterly revenue came…
-
AT&T beats wireless subscriber estimates amid bundling push
AT&T (NYSE:T) added more wireless subscribers than expected in the third quarter, helping its adjusted core earnings edge past Wall Street forecasts as the company capitalizes on its strategy of bundling discounted 5G mobile and high-speed fiber services. The telecom giant reported 405,000 net monthly bill-paying wireless phone subscriber additions, up 0.5% year over year…
-
Northern Trust tops Q3 earnings expectations as revenue climbs 3%
Northern Trust Corporation (NASDAQ:NTRS) posted third-quarter earnings on Wednesday that came in above analyst estimates, though its stock edged down 0.80% in premarket trading following the announcement. Net income per diluted common share reached $2.29, beating the $2.25 expected by analysts. Quarterly revenue came in at $2.03 billion, matching consensus forecasts and rising 3% year…
-
Stifel Financial edges higher after Q3 earnings beat expectations
Stifel Financial Corp. (NYSE:SF) shares inched up 1% in premarket trading on Wednesday after the company reported third-quarter earnings that topped Wall Street forecasts. The financial services firm posted adjusted earnings per share of $1.95 for the quarter ended September 30, 2025, beating analyst estimates of $1.89. Revenue climbed 16.7% year over year to a…
-
Arcturus Therapeutics stock plunges 50% after weak cystic fibrosis trial data
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) shares sank 50% on Wednesday after the company reported interim Phase 2 results for its cystic fibrosis treatment that failed to deliver significant improvement in lung function. The San Diego-based mRNA drug developer said its inhaled investigational therapy, ARCT-032, was generally safe and well-tolerated in the second cohort of its…
-
Biodesix shares surge 10% on expanded Bio-Rad collaboration
Biodesix (NASDAQ:BDSX) saw its stock jump 10% on Wednesday after announcing an expanded partnership with Bio-Rad Laboratories to advance the development of high-complexity oncology assays using Droplet Digital PCR technology. Under the new agreement, Biodesix will lead development, clinical validation, and regulatory submissions for in vitro diagnostic assays built on Bio-Rad’s ddPCR technology, running on…